论文部分内容阅读
原发性和继发性肺动脉高压的治疗一直是临床上的一个难题。为此Vida VL等人进行了一项研究,评价口服小剂量西地那非治疗肺动脉高压的有效性和安全性,研究共入选10名平均年龄26.8岁的肺动脉高压患者
The treatment of primary and secondary pulmonary hypertension has been a clinical problem. To this end Vida VL and others conducted a study to evaluate the efficacy and safety of oral low-dose sildenafil treatment of pulmonary hypertension in 10 cohorts of patients with a mean age of 26.8 years with pulmonary hypertension